- Home
- DOUG vs CGEN Comparison
DOUG vs CGEN Comparison
Compare DOUG & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOUG | CGEN |
|---|---|---|
| Founded | 1911 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.2M | 191.1M |
| IPO Year | 2021 | 2001 |
Fundamental Metrics
Financial Performance| Metric | DOUG | CGEN |
|---|---|---|
| Price | $2.02 | $2.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 306.4K | 230.5K |
| Earning Date | 05-05-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.68 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $955,578,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.53 | $1.30 |
| 52 Week High | $3.19 | $3.24 |
Technical Indicators
Market Signals| Indicator | DOUG | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 68.96 | 53.18 |
| Support Level | $1.70 | $2.20 |
| Resistance Level | $2.05 | $2.54 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 94.72 | 73.68 |
Price Performance
Historical ComparisonAbout DOUG Douglas Elliman Inc.
Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.